21 patients in limbo as talks on funding life-saving drug Respreza break down

Irish patients are set to lose access to life-saving lung disease drug Respreza.

Talks on funding Respreza have collapsed between the HSE and CSL Behring, the pharmaceutical company which makes it.

Twenty-one people suffering from a genetic lung disease called Alpha 1 have been using it for more than 11 years.

They were told last Friday that they will lose access to a vital drug called Respreeza at the end of the month.

Patient Gerry Finnerty from Kinsealy in North Dublin, who is 59, said: "Nobody knows what's going to happen to (us).

"There's no drug there even to ease you off - there's just a striaght trap door: 'There: it's done'."

In a statement last week CSL Behring said: “We remain committed to AATD research to improve the quality of life of people living with the condition. Based on this commitment, we are currently in discussion with health authorities in both the US and Europe to finalise a randomised, non-placebo controlled study design which seeks to demonstrate the long-term safety and efficacy of Respreeza.

“CSL Behring is evaluating clinical sites in Ireland which may then be offered the opportunity to recruit severe AATD patients.”

More in this Section

Denis Naughten to introduce reduced levy fee for independent radio stations

Brother of Tunisia terror attack victim calls on world leaders to take action

‘An absolute embarrassment’: Students slam Trinity's move to axe 'freshman' title

New direct-provision centre in Clare after 30% rise in asylum-seeker applications


Today's Stories

HSE made man’s partner feel culpable for death

Tunisia attack victim looked ‘like she was lying in the sun’

Impasse on loan sale to vulture funds

RaboDirect closure prompts review call

Lifestyle

The biggest cancer killer will take your breath away

Hopefully she had an idea...

Power of the press: Meryl Streep and Tom Hanks discuss 'The Post'

More From The Irish Examiner